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ABSTRACT
Multipotent mesenchymal stromal cell (MSC) transplantation is proposed as a novel therapy for
treating diabetes by promoting the regeneration of damaged islets. The clinical promise of such
treatments may be hampered by a high degree of donor-related variability in MSC function and
a lack of standards for comparing potency. Here, we set out to identify markers of cultured
human MSCs directly associated with islet regenerative function. Stromal cultures from nine
separate bone marrow donors were demonstrated to have differing capacities to reduce hyperglycemia in the NOD/SCID streptozotocin-induced diabetic model. Regenerative (R) and nonregenerative (NR) MSC cultures were directly compared using isobaric tags for relative and
absolute quantitation (iTRAQ)-based quantitative proteomics. A total of 1,410 proteins were
quantiﬁed resulting in the identiﬁcation of 612 upregulated proteins and 275 downregulated
proteins by 6 1.2-fold in R-MSC cultures. Elastin microﬁbril interface 1 (EMILIN-1), integrinlinked protein kinase (ILK), and hepatoma-derived growth factor (HDGF) were differentially
expressed in R-MSCs, and Ingenuity Pathway Analyses revealed each candidate as known regulators of integrin signaling. Western blot validation of EMILIN-1, ILK, and HDGF not only showed
signiﬁcantly higher abundance levels in R-MSCs, as compared with NR-MSCs, but also correlated
with passage-induced loss of islet-regenerative potential. Generalized estimating equation modeling was applied to examine the association between each marker and blood glucose reduction. Both EMILIN-1 and ILK were signiﬁcantly associated with blood glucose lowering function
in vivo. Our study is the ﬁrst to identify EMILIN-1 and ILK as prospective markers of islet regenerative function in human MSCs. STEM CELLS 2016;34:2249–2255

SIGNIFICANCE STATEMENT
The vast majority of current stem cell based clinical trials are testing the therapeutic capacity
of multipotent mesenchymal stem cells for treating a wide range of diseases. One of the critical issues plaguing the progress of these trials is a lack of suitable and reliable methods for
measuring the potency of these stem cells. This study uncovers two new potential proteins
whose abundance in human bone marrow mesenchymal stem cell cultures provides an accurate indication of their potency for repairing damaged pancreatic islets, as would be found
patients suffering from Type I diabetes. We predict these proteins to impact the development
of novel stem cell products for treating pancreatic diseases.

INTRODUCTION
Multipotent mesenchymal stromal cells, also
called mesenchymal stem cells (MSCs), are
strong candidates for regeneration-inducing
therapies during diabetes, as these cells promote islet repair and can modulate the immune
system, two aspects critical for the treatment of
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type 1 diabetes [1, 2]. Phase 2 clinical trials
using human MSCs for the treatment of type 1
diabetes mellitus are currently underway. Using
the well-established streptozotocin (STZ)-treated
diabetic NOD/SCID model [3], we have recently
shown that transplanted human MSCs can stimulate endogenous islet formation associated
C AlphaMed Press 2016
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with ductal structures resulting in improvements in islet function and glycemic control [4–6].
MSCs are found at extremely low frequency in the bone
marrow and peripheral tissues. Thus, expansion in vitro is necessary prior to clinical use. As a result, current methods for culturing MSCs generate a heterogeneous mixture of stromal cells
with variable functional properties. Unfortunately, standards
currently used to characterize the purity of MSC cultures do
not address this heterogeneity with respect to clinicallyrelevant secretory functions, such as immune suppression or
paracrine islet restoration. This was illustrated in preclinical
studies where MSC cultures demonstrated identical properties
of surface phenotype and multipotent differentiation capacity,
but showed a high degree of donor- and culture durationdependent variability in their capacity to improve glycemia
after transplantation in STZ-treated mice [4, 6]. In addition,
both intra- and inter-individual heterogeneity from MSC preparations has been previously reported to affect their functional
properties [7–12]. These studies reinforce the importance of
identifying functionally relevant potency-associated markers
that permit the identiﬁcation of MSCs with indication-speciﬁc
therapeutic potential.
We used quantitative proteomics comparing MSC cultures
with and without islet-regenerative capacity as a comprehensive system to identify MSC-speciﬁc markers associated with
islet regeneration. Herein, we establish EMILIN-1 and ILK as
markers highly associated with MSC islet-regenerative
capacity, suggesting integrin-mediated extracellular matrix signals inﬂuence the efﬁcacy of MSC-based cellular therapies in
the context of islet regeneration.

MATERIAL

AND

METHODS

Detailed materials and methods were provided as Supporting
Information.

Isolation and Propagation of MSCs from Human
Bone Marrow
Human bone marrow was drawn from the iliac crest of normal donors with informed consent from the London Health
Sciences Centre, London, Ontario and MSCs were derived as
previously described [1, 3, 4, 6, 13]. In-process data for MSC
characterization and donor-related factors are provided in
Supporting Information Table 1.

Transplantation of MSCs into STZ-treated
NOD/SCID Mice
Animal care was in accordance to the Institutional Animal
Care and Use Committee (IACUC) guidelines at the University
of Western Ontario. Immunodeﬁcient NOD/SCID mice (Jackson
Labs) were intraperitoneally-injected (i.p.) with 35 mg/kg
streptozotocin (STZ) (Sigma-Aldrich) for 5 consecutive days, as
previously described [3–6, 14]. Mice reaching hyperglycemia
on day 10 (15–25 mmol/L) were sublethally irradiated (300
cGy) and transplanted by tail vein injection with PBS or MSCs
(5 3 105). Systemic blood glucose was monitored weekly for
42 days, as previously described [1, 3–6]. MSCs from individual donors were classiﬁed as either “regenerative” (R) or
“non-regenerative” (NR) based on their capacity to reduce
hyperglycemia in transplanted mice.
C AlphaMed Press 2016
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Table 1. EMILIN-1 and ILK abundance levels were signiﬁcantly
associated with blood glucose level (“  20 mM” and “ < 20 mM”)
based on the generalized estimating equation modeling
Parameter

Estimate

Standard error

p-value

EMILIN-1
ILK
HDGF

159.14
178.84
58.19

40.83
40.86
37.39

<.0001
<.0001
.1196

The results were summarized based on the generalized estimating
equation modeling; the independent variables are day and one of
the potential markers investigated in our study. The p-values of
EMILIN-1, ILK, and HDGF are 0.0348, 0.0286, and 0.0579, respectively, in the mixed model.

Sample Preparation for iTRAQ Labeling
iTRAQ was performed using subcellular fractionations (cytosolic, membrane, nuclear) which were generated by QProteome Cell Compartment Kit (QIAGEN) according to the
manufacturer’s instructions and mass spectrometry analysis
was performed with QTof Synapt and LT-FTICR, both coupled
to a Waters nanoAcquity UPLC. A total of 1,410 proteins were
identiﬁed in all conditions, where proteins with ratios either
at >11.2 or < 21.2 comparing the islet regenerative versus
non-regenerative groups were considered to be differentially
expressed, and canonical and non-canonical pathways
(p-value  .05) activated were analyzed using Ingenuity Pathway Analysis (version 23814503).

Quantitative Infrared Western Blotting
Whole protein lysates were prepared for quantitative infrared
Western blotting, as described previously [15]. Bands were
detected using the ChemiDoc XRS 1 system for ﬂuorescent
secondary antibodies and quantiﬁed with Image Lab Software
(Bio-Rad Laboratories). The quantiﬁcation of Western blots
was performed using a loading control (i.e. gapdh or alphatubulin) according to the method described in Degasperi [16].
Three technical replicates were performed and representative
blots are shown.

Statistical Analyses
To examine the association between each identiﬁed potential
markers and blood glucose level after transplantation, the
blood glucose data between day 14 and 42 and the
expression-level average values (obtained by Western blot)
were examined for EMILIN-1, HDGF, and ILK. Blood glucose was
analyzed as binary data (i.e., “  20 mM” and “ < 20 mM”), and
its association with potential markers was assessed using generalized estimating equation (GEE) modeling. Since a blood glucose level of less than 20 mM is a clinical meaningful and
reliable indicator of islet regeneration, the GEE modeling is
considered the primary analysis of our study. The GEE modeling
allows sample-speciﬁc correlation across time (i.e., days after
MSC i.v. injection), and an auto-regression correlation structure
was chosen for the modeling based on quasi-likelihood information criterion statistics [17, 18]. In the secondary analysis
assessing the association, the blood glucose data were analyzed
as continuous data or using a mixed model, and an autoregressive covariance structure was chosen based on interpretability and Akaike’s Information Criteria. Statistical models were
implemented using SAS EG4.2.
Analysis of the area under each glucose tolerance curve
was performed with student two-tailed t-test (Fig. 1). Analysis
STEM CELLS
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Figure 1. Transplantation of islet regenerative mesenchymal stem cell (MSC) samples induces recovery from hyperglycemia and
improved glucose tolerance. (A): MSC cultures derived from nine independent donors (N 5 9) were transplanted at day 10 into STZtreated nonobese diabetic/SCID mice and segregated into MSC samples that demonstrated islet-regenerative capacity (R) and those that
did not (NR) based on signiﬁcant (p < .05) recovery from hyperglycemia at days 17–42 compared to PBS-injected controls (n 5 number
of mice transplanted/MSC sample). (B): Analysis of the area under each glucose curve was calculated for all mice transplanted with RMSC and NR-MSC samples. R-MSC samples showed signiﬁcantly reduced area under the curve. (C): Glucose tolerance tests were performed for 2 hours after intraperitoneal injection of a glucose bolus (2 mg/kg) at day 42 on mice transplanted with 3 R versus 3 NR samples. (D): Analysis of the area under each glucose tolerance curve was calculated for mice transplanted with R-MSCs and NR-MSCs. RMSC samples showed signiﬁcantly reduced area under the curve. Analysis of signiﬁcance was performed by student t-test. **, p < .01,
***, p < .001. Abbreviation: AUC, area under the curve.

of Fig. 3A, 3B was executed by Mann-Whitney two-tailed test
and one-way ANOVA followed by Tukey’s post hoc test,
respectively. A p-value < .05 was considered statistically significant. The analyses related to Figs. (1 and 3) were performed
with GraphPad Prism software version 6.0.

RESULTS
MSCs Derived from Independent Donors Showed
Variable Capacity to Reduce Hyperglycemia
in STZ-treated NOD/SCID Mice
Using the STZ-treated NOD/SCID model to assess islet regeneration [5, 6], we initially set out to identify islet regenerative (R)
and nonregenerative (NR) MSC samples, based on donordependent capacity to reduce hyperglycemia after transplantation. MSCs from nine healthy bone marrow (BM) donors were
i.v.-injected at passage 4 into NOD/SCID mice at day 10 follow-

www.StemCells.com

ing STZ-treatment from days 1–5 (Fig. 1A). Blood glucose levels
were measured weekly for up to 42 days post STZ-treatment.
Compared with PBS-injected controls that remained severely
hyperglycemic (>25 mmol/L), injection of MSCs (5 3 105)
derived from ﬁve independent donors led to signiﬁcantly
improved systemic glycemia from days 14–42 (Fig. 1A, 1B). In
contrast, mice injected with MSCs from four other independent
donors maintained blood glucose levels similar to PBS injected
controls (Fig. 1A, 1B). Glucose tolerance tests were also performed after i.p. injection of a glucose bolus (2 mg/kg) at day
42 on mice transplanted with three NR-MSC versus three RMSC samples. Mice transplanted with R-MSC demonstrated signiﬁcantly improved glucose tolerance (Figure 1C, 1D). These
data conﬁrm that the ability of transplanted BM-derived MSCs
to improve glucose control varied between donors and could
be clearly segregated into either islet R or NR sub-groups.
Importantly, we have previously established that transplanted
human BM-MSCs do not acquire insulin expression in vivo. In
C AlphaMed Press 2016
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Figure 2. Pathway enrichment analysis showed enriched integrin and EMILIN-1 signaling pathways. (A): Top canonical pathways that
were signiﬁcantly enriched from the differentially regulated protein dataset. The orange straight line represents the threshold for signiﬁcantly enriched categories, where the p-value is .05 (or—log p-value of 1.30) found by a modiﬁed Fisher’s exact test. The top canonical
pathways are indicated (cut-off of p-value of .001 or 2log of p-value of 3.0; z-score > 1.0). The orange colored bars indicate predicted
pathway activation in R-MSC samples and the blue bar indicates pathway inhibition. The overall activation/prediction state of canonical
pathways are predicted based on a z-score algorithm (i.e., the darker the color of the bars, the higher the z-score). The orange points
connected by a thin line represent the ratio of proteins in a given category obtained from the differently regulated protein dataset
divided by the total number of proteins present in that pathway. (B): EMILIN-1 pathway was found to be a unique noncanonical pathway. EMILIN-1 is represented here with its pathway members. Highlighted in magenta are known targets of the integrin canonical pathway. (C): EMILIN-1 and ILK relationships to the integrin pathway were inquired using the Path Explorer’s tool. (D): Hepatoma-derived
growth factor (HDGF) relationship to the integrin pathway was enquired using the Path Explorer’s tool. The shortest paths to integrin
are depicted here. Dashed lines represent indirect relationships and nondashed lines represent direct relationships. Data analysis was
performed using Ingenuity Pathway Analysis version 23814503. Abbreviations: ECM, extracellular matrix; EMILIN-1, Elastin microﬁbril
interface 1; ILK, integrin-linked protein kinase.

contrast, injected BM MSCs engraft murine tissues and stimulate the formation of small islet clusters in the recipient pancreas via undetermined secretory activities [3–5].

Quantitative Proteomic Analysis of R- and NR-MSC
Samples Identified Prospective Markers Associated
with Islet Regeneration
Based on this in vivo platform, MSCs from R-MSCs (n 5 4) and
NR-MSCs (n 5 2) samples were expanded to generate sufﬁcient
cell numbers to allow quantitative proteomic comparison
between sub-groups. We applied iTRAQ-based quantitative proteomics following upstream protein fractionation of cytosolic,
nuclear and membrane subcellular fractions with subsequent
puriﬁcation of peptides based on isoelectric point using off-gel
fractionation. A total of 1,410 proteins were identiﬁed and
quantiﬁed by 1D LC-MS-MS, where 612 proteins were observed
to be upregulated and 275 downregulated in R-MSCs by 6 1.2
C AlphaMed Press 2016
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fold. To further ﬁlter the data using a non-biased approach, we
analyzed differently regulated proteins using Ingenuity Pathway
Analysis (IPA) to search for canonical and non-canonical signaling pathways signiﬁcantly modulated in R-MSCs (Fig. 2A). These
analyses revealed that nine canonical pathways were signiﬁcantly activated in R-MSCs, including EIF2 and mTOR signaling,
remodeling of epithelial junctions, RhoA signaling and integrin
signaling (Fig. 2A, orange bars, p < .00001), and that 1 pathway
was signiﬁcantly repressed in R-MSCs, namely the RhoGDI signaling pathway (Fig. 2A, blue bar, p < .0001). Of these 10
enriched pathways, 8 (mTOR, RhoA, Integrin, Rho family
GTPases, Actin-based motility by Rho, Rac, RhoGDI and PI3K/
AKT) are known to be engaged following ECM-integrin activation. Interestingly, both the Target of Rapamycin (mTOR) and
Ras homology, member A (RhoA) pathways can be activated by
integrin engagement via the activity of integrin-linked kinase
(ILK) and focal adhesion kinase (FAK) [19], respectively. Based
STEM CELLS
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on these results highlighting the importance of ECM-integrin
engagement from R-MSCs, candidate proteins involved in the
integrin signaling pathway were further scrutinized using IPA to
identify proteins for further functional validation as potential
markers of R-MSCs. Several canonical intracellular integrin pathway proteins were found to be differentially regulated in RMSCs, as highlighted in Supporting Information Fig. 1. More
notably, examination of differentially regulated proteins participating in non-canonical integrin pathways uncovered the
extracellular matrix protein EMILIN-1 (Fig. 2B). As depicted in
Fig. 2C, EMILIN-1 interacts directly with integrin alpha and beta
subunits, as well as with other players involved in the integrinILK pathway, including PTEN, PI3K, and AKT, but do not directly
interact with ILK. A second extracellular matrix protein upregulated in R-MSCs, heparin-binding HDGF, was also shown to have
an indirect relationship with the integrin signaling pathway
through TGFB1, COL1A1 or heparin, putting further accent on
the potential importance of integrin pathways (Fig. 2D). Based
on these bioinformatics results along with the previously
reported importance of the ECM-integrin signaling complex in
islet regeneration [4], EMILIN-1, HDGF, and ILK were selected
for further validation as predictive markers of islet regenerative
capacity.

Validation by Western Blot Showed that EMILIN-1, ILK,
and HDGF were Prospective Markers Associated with
Islet-regenerative Potential
To validate the quantitative iTRAQ LC-MS/MS results and to
directly assess the importance of three prospective markers associated with islet regeneration, EMILIN-1, ILK, and HDGF total
abundance levels were examined by Western blotting using independently derived whole cell lysates from 4 R- and 4 NR-MSC cultures. All three prospective markers showed signiﬁcantly increased
abundance levels in R-MSCs when compared with NR-MSCs (Fig.
3A). Our previous work has also demonstrated that prolonged
expansion of R-MSCs resulted in loss of MSC potency for the
capacity to reduce hyperglycemia after transplantation [4]. These
studies reported that islet regenerating capacity was consistently
maintained for up to four passages and then progressively
decreased with cell expansion until being lost completely by passage eight. As a measure of prospective biological validation for
the protein markers discovered, we used quantitative Western
blotting to measure the abundance levels of EMILIN-1, HDGF, and
ILK in islet-regenerative MSC cultures subjected to prolonged culture. This experiment was performed using an R-MSC sample (R2)
that was shown to progressively lose glucose lowering function
with extended passage in a previous publication [5]. All three of
the prospective markers showed a progressive and signiﬁcant
decrease in relative abundance levels with increased passage
number (Fig. 3B). By passage 8, when glucose lowering function
was completely lost, abundance levels of EMILIN-1, HDGF, and ILK
had reduced by 1.80-fold, 1.52-fold, and 1.41-fold, respectively.
These results indicated that decreased abundance of EMILIN-1,
HDGF, and ILK in R-MSCs correlated with passage-induced loss of
islet regenerating function after transplantation in vivo.
To examine the association between each potential
markers to the reduction of blood glucose level after MSC
transplantation, the abundance level values obtained for each
marker (Fig. 3A) and the blood glucose data between day 14
and 42 (Fig. 1A) were used in the primary analysis using a
generalized estimating equation (GEE) modeling (Table 1). A

www.StemCells.com

2253

statistically signiﬁcant association between EMILIN-1 and ILK
abundance and reduced blood glucose concentration after
transplantation was revealed (blood glucose analyzed as
binary data, p-value: EMILIN-1, < .0001; ILK, < .0001) (Table 1).
Furthermore this correlation was also upheld when blood glucose concentration was analyzed as continuous data (p-value:
EMILIN-1 < .0348; ILK < .0286). While these analyses also suggested that HDGF may also serve as a prospective marker, its
association with blood glucose concentration did not quite
reach statistical signiﬁcance using GEE (p-value: blood glucose
as binary data, 0.1196; as continuous data, 0.0579) (Table 1).

DISCUSSION
Our study demonstrates that EMILIN-1 and ILK are novel markers
of islet regenerative capacity in cultured MSC samples. HDGF
likely represents a potential secretory marker as well; however,
due to limited sample size, a statistically signiﬁcant association
between HDGF and blood glucose concentration was not
achieved. Although the identiﬁcation of the speciﬁc role of these
markers in islet regeneration warrants further mechanistic study,
the work presented here highlights the variability that exists
among stromal cultures and the importance of ﬁnding reliable
markers related to therapeutic effectiveness after transplantation.
To date, few proteins have been identiﬁed that show varied
abundance levels in stromal cultures correlating directly with in
vivo regenerative function. Selection of candidate markers for further validation was based on our bioinformatics results and previous ﬁndings highlighting the importance of ECM-integrin and
angiogenesis in islet regeneration [4]. Indeed, EMILIN-1, ILK, and
HDGF proteins selected for the validation work are all known
interactors of the integrin pathway, as demonstrated by pathway
enrichment analysis, and also represent known effectors of angiogenesis [20–23], a process that has been postulated to play a
crucial role in MSC mediated tissue repair [4–6]. In addition,
EMILIN-1 and ILK are important regulatory factors in cell proliferation, survival, matrix interaction and adhesion via integrins
[24–26]. By being an upstream activator of the integrin pathway,
EMILIN-1 could inﬂuence the activity of ILK.
EMILIN-1 is an extracellular matrix (ECM) glycoprotein previously shown to regulate elastogenesis [27], lymphatic valve
formation and maintenance [24] and cell proliferation via the
interaction with integrins a4b1 and a9b1 [28]. HDGF is a
known heparin-binding protein shown to induce the chemotaxis and growth of smooth muscle cells [29, 30]. ILK is a 59kDa ankyrin-repeat containing serine/threonine protein
pseudo-kinase that interacts with the cytoplasmic domain of
b1 and b3 integrin receptors and is therefore a critical component of the integrin-ECM signaling complex [31]. In line
with these ﬁndings, Bell et al. had previously reported the
up-regulation of genes translating to known secreted proteins
from R-MSCs involved in regulating the ECM, including several
matrix metalloproteases (MMP1 and MMP13) and targets
implicated in angiogenesis (HGF, FGF16 and ANGPTL4), as well
as transcripts encoding integrins (integrin b8 and a8) [4].

SUMMARY
Based on the known functions of the markers that we identiﬁed, we postulate that increased abundance of EMILIN-1 and
C AlphaMed Press 2016
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Figure 3. EMILIN-1, ILK, and HDGF are MSC prospective markers associated with islet-regenerative potential. (A): Western blot analyses
of putative islet regenerative MSC markers expressed in islet regenerative (N 5 4) versus nonregenerative (N 5 4) MSC samples. Data
were obtained from three independent experiments and are expressed as mean 6 S.E.M. Mann-Whitney two-tailed test was performed.
*, p < .05. (B): We have previously shown that islet regenerative capacity is decreased with prolonged MSC expansion in culture. MSC
from islet regenerative sample (R2) was expanded for up to eight passages and Western blots were performed at increasing passage
(P4, P6, and P8). Abundance levels for each putative marker were quantiﬁed by relative band intensity densitometry. Data were
obtained from three independent experiments and are expressed as mean 6 S.E.M. One-way ANOVA with Tukey’s multiple comparison
post-test was performed. *, p < 0.05,**, p < .01, ***, p < .001. GAPDH: glyceraldehyde 3-phosphate dehydrogenase, NR: nonregenerative, P: passage, R: regenerative, a-tub: Alpha-Tubulin. Abbreviations: EMILIN-1, Elastin microﬁbril interface 1; HDGF, hepatomaderived growth factor; ILK, integrin-linked protein kinase; MSC, mesenchymal stromal cell.

HDGF in transplanted R-MSCs acts to increase MSC survival
after transplantation through integrin engagement and may
modify the ECM in the regenerating pancreas to promote islet
recovery/regeneration after beta cell injury in vivo. The data
presented here indicates for the ﬁrst time that increased
abundance levels of EMILIN-1 and ILK may provide a useful
means for the standardization of human stromal cultures and
a basis for the development of in vitro potency assays for
MSC-based secretory products to stimulate islet regeneration.
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